Walleye Capital’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Walleye Capital’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-64,791	Closed	-$4.14K	–	4650
2022 Q4	$4.14K	Hold	64,791	–	–	﹤0.01%	2884
2022 Q3	$4K	Hold	64,791	–	–	﹤0.01%	2987
2022 Q2	$6K	Buy	64,791 +17,954	+38%	+$3.71K	﹤0.01%	2105
2022 Q1	$11K	Sell	46,837 -2,515	-5%	-$802	﹤0.01%	2088
2021 Q4	$33K	Buy	+49,352	New	+$34.2K	﹤0.01%	1838

Walleye Capital's BIOTW Position: Q1 2023 in Review

Walleye Capital sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 64,791 shares — an estimated $4.14K sold.

Walleye Capital first reported a position in BIOTW in Q4 2021 and held it in 5 quarters. The position peaked at $33K in Q4 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Walleye Capital reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Walleye Capital sold 64,791 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $4.14K.
Walleye Capital first reported a position in Biotech Acquisition Company Warrant in Q4 2021 and held it in 5 quarters.
Walleye Capital's Biotech Acquisition Company Warrant position peaked at $33K in Q4 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Walleye Capital's 13F filing for Q1 2023, filed 15 May 2023.